<unk>  (BXM), sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B flu. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.<unk>  was developed as a prodrug strategy, with its metabolism releasing the active agent,<unk>  acid (BXA). BXA then functions as enzyme inhibitor, targeting the influenza virus' cap-dependent endonuclease activity, used in "cap snatching" by the virus' polymerase complex, a process essential to its life-cycle. The most common side effects of<unk>  include diarrhea, bronchitis, nausea, sinusitis and headache. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Baloxavir marboxil
Fosamprenavir
Atazanavir/ritonavir
Amprenavir
Ledipasvir/sofosbuvir
Nelfinavir
Lamivudine/zidovudine
Lamivudine/raltegravir